CM
KROS icon

Caption Management’s Keros Therapeutics KROS Stock Holding History

Caption Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-392,900
Closed -$4M – 1695
2025
Q1 		$4M Buy
+392,900
New +$4.56M 0.04% 467
2024
Q2 		– Sell
-23,600
Closed -$1.56M – 1351
2024
Q1 		$1.56M Buy
+23,600
New +$1.4M 0.02% 609

Other funds holding KROS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Caption Management's KROS Position: Q1 2026 in Review

Caption Management sold out of Keros Therapeutics (KROS) in Q1 2026, closing a stake of 29,500 shares — an estimated $601K sold.

Caption Management first reported a position in KROS in Q3 2022 and held it in 6 quarters. The position peaked at $1.09M in Q1 2025. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Caption Management reported no remaining Keros Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Caption Management sold 29,500 Keros Therapeutics shares in Q1 2026, an estimated $601K.
  • Caption Management first reported a position in Keros Therapeutics in Q3 2022 and held it in 6 quarters.
  • Caption Management's Keros Therapeutics position peaked at $1.09M in Q1 2025.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.